Results 281 to 290 of about 388,360 (386)
Beyond Risk Reduction: Vigilant Trust in Artificial Intelligence Based on Evidence from China. [PDF]
Ding W, Wu Y, Wang J.
europepmc +1 more source
Template-based prediction of vigilance fluctuations in resting-state fMRI
Maryam Falahpour +3 more
openalex +2 more sources
Mechanochromic Organic Materials: Molecular Mechanisms and Multidimensional Applications
Mechanochromic (MC) organic materials change color in response to mechanical force. This review elucidates the molecular mechanisms (e.g., aggregation‐induced emission, AIE) and explores their multidimensional applications in sensors, anti‐counterfeiting, biomedical devices, and structural health monitoring, providing a roadmap for future smart ...
Xiaozhe Yin +5 more
wiley +1 more source
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley +1 more source
Circadian Variations in Cognitive Performance Among Patients With Narcolepsy and Obstructive Sleep Apnea: A Comparative Study. [PDF]
Cheng Y +10 more
europepmc +1 more source
Objectives The aim of this study is to generate hypotheses about unknown drugs associated with the onset or worsening of Raynaud's phenomenon (RP) and to explore their potential pathophysiologic mechanisms through a mixed disproportionality/clustering analysis from the World Health Organization (WHO) pharmacovigilance database.
Alex Hlavaty +4 more
wiley +1 more source
Nip it in the bud: the role of vigilant leadership, knowledge sharing, and safety performance. [PDF]
Li Q, Yang SL, Ye L.
europepmc +1 more source
Background The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasing immunosuppressive (IST) and anti‐fibrotic therapies available. However, their real‐world use remains unclear. Objectives To analyze treatment trends and the effect of IST and anti‐fibrotic therapies on ILD progression ...
Corrado Campochiaro +17 more
wiley +1 more source

